Related references
Note: Only part of the references are listed.Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean McBride et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma
Amanda J. Koong et al.
PRACTICAL RADIATION ONCOLOGY (2020)
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Aaron J. Grossberg et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma A Multicenter Phase 3 Randomized Clinical Trial
Rui You et al.
JAMA ONCOLOGY (2020)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database
Devalkumar J. Rajyaguru et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief
Milly Buwenge et al.
JOURNAL OF PAIN RESEARCH (2018)
Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer
Jonathan W. Lischalk et al.
JOURNAL OF GASTROINTESTINAL CANCER (2018)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer
Lauren M. Rosati et al.
SEMINARS IN RADIATION ONCOLOGY (2017)
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study
T. Comito et al.
EJSO (2017)
Current progress in immunotherapy for pancreatic cancer
Kelly Foley et al.
CANCER LETTERS (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer
Chad G. Rusthoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
Andrew G. Renehan et al.
LANCET ONCOLOGY (2016)
Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer
Ting-Shi Su et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer
Nicholas Trakul et al.
SEMINARS IN RADIATION ONCOLOGY (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Constructing inverse probability weights for marginal structural models
Stephen R. Cole et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Martin F. Muers et al.
LANCET (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
